This phase 1b trial investigated the feasibility, safety, and efficacy of different combinations of neoadjuvant nivolumab ± ipilimumab with domatinostat in patients with stage III melanoma, stratified according to the IFN-γ score from a baseline tumor biopsy. The gene discussed is IFNG; the disease is melanoma.